Enliven Therapeutics, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Enliven announced positive Phase 1 clinical data for ELVN-001 (CML treatment): 61% major molecular response (MMR) at 80 mg once daily, with 67% MMR in earlier-line patients. FDA granted Fast Track Designation and aligned on Phase 3 trial (ENABLE-2) design; 80 mg QD selected as recommended dose. Company has $895.2M cash (up from $462.6M at year-end 2025), funding operations into 2030. Q2 2026 net loss was $32.5M versus $25.3M in Q2 2025.
Why this rating
Strong clinical validation and FDA regulatory progress de-risk lead program; 94% cash increase materially extends runway. At $836M market cap, positive Phase 1 and regulatory alignment are meaningful catalysts for Phase 3 initiation; typical for clinical-stage biotech at this stage.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.